FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200559079> ?p ?o ?g. }

• W4200559079 endingPage "100877" @default.
• W4200559079 startingPage "100877" @default.
• W4200559079 abstract "The first high-quality clinical trial to support ultrahypofractionated whole-breast irradiation (ultra-HF-WBI) for invasive early-stage breast cancer (ESBC) was published in April 2020, coinciding with the beginning of the COVID-19 pandemic. We analyzed adoption of ultra-HF-WBI for ductal carcinoma in situ (DCIS) and ESBC at our institution after primary trial publication.We evaluated radiation fractionation prescriptions for all patients with DCIS or ESBC treated with WBI from March 2020 to May 2021 at our main campus and regional campuses. Demographic and clinical characteristics were extracted from the electronic medical record. Treating physician characteristics were collected from licensure data. Hierarchical logistic regression models identified factors correlated with adoption of ultra-HF-WBI (26 Gy in 5 daily factions [UK-FAST-FORWARD] or 28.5 Gy in 5 weekly fractions [UK-FAST]).Of 665 included patients, the median age was 61.5 years, and 478 patients (71.9%) had invasive, hormone-receptor-positive breast cancer. Twenty-one physicians treated the included patients. In total, 249 patients (37.4%) received ultra-HF-WBI, increasing from 4.3% (2 of 46) in March-April 2020 to a high of 45.5% (45 of 99) in July-August 2020 (P < .001). Patient factors associated with increased use of ultra-HF-WBI included older age (≥50 years old), low-grade WBI without inclusion of the low axilla, no radiation boost, and farther travel distance (P < .03). Physician variation accounted for 21.7% of variance in the outcome, with rate of use of ultra-HF-WBI by the treating physicians ranging from 0% to 75.6%. No measured physician characteristics were associated with use of ultra-HF-WBI.Adoption of ultra-HF-WBI at our institution increased substantially after the publication of randomized evidence supporting its use. Ultra-HF-WBI was preferentially used in patients with lower risk disease, suggesting careful selection for this new approach while long-term data are maturing. Substantial physician-level variation may reflect a lack of consensus on the evidentiary standards required to change practice." @default.
• W4200559079 created "2021-12-31" @default.
• W4200559079 creator A5004127843 @default.
• W4200559079 creator A5009965176 @default.
• W4200559079 creator A5011388011 @default.
• W4200559079 creator A5012168301 @default.
• W4200559079 creator A5012745900 @default.
• W4200559079 creator A5016731809 @default.
• W4200559079 creator A5020297880 @default.
• W4200559079 creator A5024466689 @default.
• W4200559079 creator A5030710794 @default.
• W4200559079 creator A5037393115 @default.
• W4200559079 creator A5041542657 @default.
• W4200559079 creator A5041793550 @default.
• W4200559079 creator A5047507534 @default.
• W4200559079 creator A5053177306 @default.
• W4200559079 creator A5059063695 @default.
• W4200559079 creator A5059988668 @default.
• W4200559079 creator A5063708099 @default.
• W4200559079 creator A5064688944 @default.
• W4200559079 creator A5073701206 @default.
• W4200559079 creator A5078458765 @default.
• W4200559079 creator A5079305500 @default.
• W4200559079 creator A5089277393 @default.
• W4200559079 creator A5090279568 @default.
• W4200559079 date "2022-03-01" @default.
• W4200559079 modified "2023-10-14" @default.
• W4200559079 title "Adoption of Ultrahypofractionated Radiation Therapy in Patients With Breast Cancer" @default.
• W4200559079 cites W1835103671 @default.
• W4200559079 cites W1987423317 @default.
• W4200559079 cites W1990637325 @default.
• W4200559079 cites W1992332433 @default.
• W4200559079 cites W2014762670 @default.
• W4200559079 cites W2019039351 @default.
• W4200559079 cites W2069968482 @default.
• W4200559079 cites W2086518082 @default.
• W4200559079 cites W2092530442 @default.
• W4200559079 cites W2096499183 @default.
• W4200559079 cites W2103608035 @default.
• W4200559079 cites W2109142755 @default.
• W4200559079 cites W2210583157 @default.
• W4200559079 cites W2259733397 @default.
• W4200559079 cites W2310700188 @default.
• W4200559079 cites W2468535384 @default.
• W4200559079 cites W2556451146 @default.
• W4200559079 cites W2618058430 @default.
• W4200559079 cites W2757600068 @default.
• W4200559079 cites W2770327119 @default.
• W4200559079 cites W3013394714 @default.
• W4200559079 cites W3016251265 @default.
• W4200559079 cites W3022548009 @default.
• W4200559079 cites W3044013897 @default.
• W4200559079 cites W3087319988 @default.
• W4200559079 cites W3196987919 @default.
• W4200559079 doi "https://doi.org/10.1016/j.adro.2021.100877" @default.
• W4200559079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35387420" @default.
• W4200559079 hasPublicationYear "2022" @default.
• W4200559079 type Work @default.
• W4200559079 citedByCount "2" @default.
• W4200559079 countsByYear W42005590792022 @default.
• W4200559079 countsByYear W42005590792023 @default.
• W4200559079 crossrefType "journal-article" @default.
• W4200559079 hasAuthorship W4200559079A5004127843 @default.
• W4200559079 hasAuthorship W4200559079A5009965176 @default.
• W4200559079 hasAuthorship W4200559079A5011388011 @default.
• W4200559079 hasAuthorship W4200559079A5012168301 @default.
• W4200559079 hasAuthorship W4200559079A5012745900 @default.
• W4200559079 hasAuthorship W4200559079A5016731809 @default.
• W4200559079 hasAuthorship W4200559079A5020297880 @default.
• W4200559079 hasAuthorship W4200559079A5024466689 @default.
• W4200559079 hasAuthorship W4200559079A5030710794 @default.
• W4200559079 hasAuthorship W4200559079A5037393115 @default.
• W4200559079 hasAuthorship W4200559079A5041542657 @default.
• W4200559079 hasAuthorship W4200559079A5041793550 @default.
• W4200559079 hasAuthorship W4200559079A5047507534 @default.
• W4200559079 hasAuthorship W4200559079A5053177306 @default.
• W4200559079 hasAuthorship W4200559079A5059063695 @default.
• W4200559079 hasAuthorship W4200559079A5059988668 @default.
• W4200559079 hasAuthorship W4200559079A5063708099 @default.
• W4200559079 hasAuthorship W4200559079A5064688944 @default.
• W4200559079 hasAuthorship W4200559079A5073701206 @default.
• W4200559079 hasAuthorship W4200559079A5078458765 @default.
• W4200559079 hasAuthorship W4200559079A5079305500 @default.
• W4200559079 hasAuthorship W4200559079A5089277393 @default.
• W4200559079 hasAuthorship W4200559079A5090279568 @default.
• W4200559079 hasBestOaLocation W42005590791 @default.
• W4200559079 hasConcept C121608353 @default.
• W4200559079 hasConcept C126322002 @default.
• W4200559079 hasConcept C143998085 @default.
• W4200559079 hasConcept C151956035 @default.
• W4200559079 hasConcept C2780862961 @default.
• W4200559079 hasConcept C509974204 @default.
• W4200559079 hasConcept C530470458 @default.
• W4200559079 hasConcept C71924100 @default.
• W4200559079 hasConceptScore W4200559079C121608353 @default.
• W4200559079 hasConceptScore W4200559079C126322002 @default.
• W4200559079 hasConceptScore W4200559079C143998085 @default.
• W4200559079 hasConceptScore W4200559079C151956035 @default.

• next